Australian medical robotics company Vexev announced it has raised $6 million in new funding to accelerate the path to FDA 510(k) clearance and U.S. commercialization of VxWave, its robotic tomographic ultrasound platform, designed to improve access to standardized vascular imaging. The raise brings Vexev's total funding to date to $19 million.
Cardiovascular disease is the world's leading cause of death, claiming nearly 20 million lives each year. Yet access to high-quality vascular imaging remains constrained by specialist availability and inconsistent image acquisition. Vexev is developing autonomous robotic imaging technology designed to help address that challenge.
VxWave combines robotics, artificial intelligence and ultrasound imaging to automate vascular ultrasound acquisition. The platform is being developed for upper-limb imaging, with dialysis vascular access as its initial application, where patients require frequent vascular monitoring and healthcare providers face increasing demand for efficient, standardized imaging.
The announcement follows successful results in multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows. During the multi-site study, the VxWave demonstrated a 94% scanning success rate for autonomous vascular imaging by non-specialist clinical staff, with the potential ability to standardize vascular imaging designed to improve consistency and potentially decreasing time to diagnosis and treatment.
"We are starting with dialysis patients because the clinical need is clear, but our vision is much broader: to build an autonomous imaging platform that helps clinicians make faster, more consistent and more informed decisions across vascular disease," Vexev CEO John Carroll said.
Beyond dialysis vascular access, Vexev intends to expand its autonomous imaging platform into additional vascular disease applications like cardiovascular and peripheral artery disease, while building the clinical evidence needed to support future AI-enabled decisions.
The fundraise round included participation from existing investors Blackbird Ventures, Neotribe Ventures, Startmate and Horizon, together with new investors TreeArc Investment Group, TEN13, Bioshore Ventures and Alumni Ventures. Funding will support regulatory activities, manufacturing scale-up and commercialization.
